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Abstract Emerging concepts suggest that a multitude of
pathology ranging from misfolding of alpha-synuclein to
neuroinflammation, mitochondrial dysfunction, and neu-
rotransmitter driven alteration of brain neuronal networks
lead to a syndrome that is commonly known as Parkinson’s
disease. The complex underlying pathology which may
involve degeneration of non-dopaminergic pathways leads
to the expression of a range of non-motor symptoms from
the prodromal stage of Parkinson’s to the palliative stage.
Non-motor clinical subtypes, cognitive and non-cognitive,
have now been proposed paving the way for possible
subtype specific and non-motor treatments, a key unmet
need currently. Natural history of these subtypes remains
unclear and need to be defined. In addition to in vivo
biomarkers which suggest variable involvement of the
cholinergic and noradrenergic patterns of the Parkinson
syndrome, abnormal alpha-synuclein accumulation have
now been demonstrated in the gut, pancreas, heart, salivary
glands, and skin suggesting that Parkinson’s is a multi-
organ disorder. The Parkinson’s phenotype is thus not just
a dopaminergic motor syndrome, but a dysfunctional multi-
neurotransmitter pathway driven central and peripheral
nervous system disorder that possibly ought to be consid-
ered a syndrome and not a disease.
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Background
In 1817, James Parkinson, the English physician, described
a syndrome and he named Paralysis Agitans (An Essay on
the Shaking Palsy), which was subsequently termed
Parkinson’s disease (PD) by Jean-Marie Charcot in view of
his initial description. (Parkinson 1817) Despite including
significant details regarding many of its key non-motor
symptoms including sleepiness, fatigue and dysautonomia
over the years, PD has almost become synonymous with a
dopamine deficiency motor syndrome. Clearly, this posi-
tion has been reinforced by the dramatic effect of levodopa
in relieving the motor features of PD, which whilst revo-
lutionizing the outlook for patients has fallen well short in
addressing the non-motor syndrome (NMS) (Langston
2006). This deficiency in clinical practice is not surprising
when one considers that it was not until the early 2000’s
that the first validated tools to comprehensively evaluate
the complex medley of NMS in PD were developed
(Chaudhuri et al. 2006). These objective measures laid bare
the extent of the NMS and its major impacts on quality of
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life in PD (Martinez-Martin et al. 2011), as well as high-
lighting the need for specific focused non-motor therapies
(Schrag et al. 2015b).
The multi-focal and multi-neurotransmitter driven
pathology of PD has been emphasized by the landmark
work of Braak et al. who suggested that a ‘‘bottom-up’’ six-
stage pathological process could account for most cases
studied neuropathologically (Braak et al. 2003). This work
has proposed that alpha-synuclein pathology critically
resulting in neuronal Lewy body deposition and cell death
spreads from regions interfacing with the ‘‘environment’’.
In this model, regions including the olfactory bulb and the
enteric nervous system with its connections to the medulla
through the dorsal motor nucleus of the vagus nerve act as
a ‘conduit’ for a spreading pathology perhaps mediated by
a prion-like process (Klingelhoefer and Reichmann 2015).
Such a model allows both dopaminergic and non-
dopaminergic populations to be differentially affected and
in so doing may permit insights into the motor and NMS.
Whilst by no means perfect, this concept of a multi-neu-
rotransmitter, multi-organ (brain and peripheral nervous
system) disorder is now well established in the literature
with supportive pathological and biomarker driven projects
(Jellinger 2015; Sauerbier et al. 2016). A multitude of
factors are now thought to underlie the final clinical
expression of the complex disorder that is PD and some are
listed in Table 1. All of above would suggest that PD is a
heterogeneous syndrome defined by a variable collection of
signs and symptoms that manifest to differing extents
within individual patients. However, we are conscious of
the fact that some would argue that robust evidence base
for PD being a multisystem disorder with heterogenic
genetic basis is lacking. We consider these facts and
provide evidence to support the syndromic nature of
Parkinson’s and debate whether Parkinson’s should be
called a disease or a syndrome. We will thus use the term
Parkinson’s disease (PD) interchangeably with Parkinson’s
syndrome in this paper.
Pathological and neurotransmitter basis
of the Parkinson’s syndrome: it is not all dopamine
The clinical phenotype of PD is variable and a wide range of
NMS underpin both the prodromal and clinical stages of PD
(Schrag et al. 2015a; Zis et al. 2015). These NMS range
from sleep dysfunction, such as rapid eye movement
behavior disorder (RBD) to cognitive dysfunction and apa-
thy, which may arise from a varying density of Lewy body
deposition and non-dopaminergic patterns of neurodegen-
eration in PD (Jellinger 2012) and response to medications.
The heterogeneity of Parkinson’s is also underpinned by a
complex pathophysiology which ranges from misfolding of
alpha-synuclein to amyloid and tau protein deposition,
neuroinflammation, mitochondrial dysfunction, genetic and
epigenetic factors, as well as the brainstem origin of the
condition. The clinical phenotypic variations, therefore,
represent the consequence of widespread brain and periph-
eral Lewy body pathology and not a single neuronal struc-
ture, such as the substantia nigra or isolated loss of the
dopamine neurotransmitter system (Jellinger 2012; Todor-
ova et al. 2014). The neurotransmitter systems affected are
widespread and the convergence of deficits in multiple
transmitter pathways which include the dopaminergic,
cholinergic, noradrenergic, and serotonergic systems among
others. These possibly drive abnormal central brain network
Table 1 List of proposed mechanisms and pathophysiological basis for the expression of clinical signs of Parkinson’s disease
Genetics and epigenetics
LRRK2, GBA mutations, and higher rates of PD in certain ethnic groups, such as Ashkenazi Jews, Inuit populations
Dietary or occupational exposure to organic toxins (insecticides for example)
Gene interaction with environment (higher risk in agricultural communities, lower risk in smokers, head trauma)
Alpha-synuclein abnormalities
Misfolding, oligomeric form, and altered proteostasis and neurotoxicity
Susceptibility of ageing brain
Synaptic dysfunction and loss of synaptic level functioning
Prion-like intra axonal transport (gut to brain)
Amyloid and Tau deposition particularly in older PD and dementia
Mitochondrial dysfunction (reduced complex 1 activity)
Oxidative stress causing cell damage and death
Neuroinflammation which may trigger misfolding of alpha-synuclein
Altered gut microbiota and reduced mucin increasing gut permeability and possible inflammatory spread to brain
Neurotransmitter linked abnormalities (selective or in combination as detailed in the paper)
Alteration in cerebral functional network and signaling function
Adenosine receptor abnormalities
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activity which results in the clinical expression of the highly
heterogeneous Parkinson syndrome (Fig. 1).
Selective vulnerability of non-dopaminergic
neurons
The Braak hypothesis of alpha-synuclein accumulation
starting in the lower medulla and the anterior olfactory
bundle with a subsequent spread via pons to the midbrain
would potentially affect a range of non-dopaminergic
nuclei along the route, including the locus coeruleus and
the raphe area, even before there was any significant
involvement of substantia nigra (Braak et al. 2003). A
number of authors have reported that non-dopaminergic
nuclei may degenerate at a faster rate and sometimes to a
greater degree than dopaminergic neurons in the early and
prodromal stages of PD. Indeed, a number of studies have
reported that there may be a greater loss of cholinergic
pedunculopontine nucleus neurons and substance P—
Fig. 1 Multi-system and multi-neurotransmitter dysfunction in PD. NMS non-motor symptoms; OH orthostatic hypotension, MCI mild
cognitive impairment Adapted from Chaudhuri and Fung (2016)
Parkinson’s: a syndrome rather than a disease?
123
containing neurons in dorsal motor nucleus of the vagus
(over 70%) with relative sparing (\5%) of tyrosine
hydroxylase-immunoreactive neurons in the dopaminergic
system (Hirsch et al. 1987; Jellinger 1987; Halliday et al.
1990). In addition, Jellinger (2012) has also shown that
neuronal loss in the dorsal motor nucleus of vagus (DMV)
could be as profound as that in the substantia nigra (SN). It
is well accepted that the DMV is a one of main centers for
autonomic signaling and may be responsible for autonomic
symptoms, such as constipation, which is commonly seen
in prodromal stage of PD. Differences in the onset age of
PD (i.e., late versus early) may also imply a brainstem
pathology dominant clinical picture in the early onset
disease, while in late onset disease, brainstem pathology is
associated with cortical Lewy body deposition. The reasons
underlying this age-related discrepancy are not resolved
but may relate to issues of depleted neural reserve and
immune-competence (Halliday et al. 2011).
Peripheral involvement in PD
The syndromic nature of PD is also evident in the fact that
there is pathological involvement of many peripheral
organs as discussed briefly below. For instance, the central
noradrenergic system is prominently involved in the neu-
ropathology of PD. In addition, noradrenaline is recognized
as a key transmitter in the sympathetic nervous system,
which in particular innervates the vascular system and the
heart. Using in vivo cardiac meta-(123)I-iodobenzyl-
guanedine (MIBG) or PET 18F-fluorodopamine (FD),
imaging has demonstrated the loss of noradrenergic cardiac
innervation in patients with early PD (Fig. 2). Further
evidence of possible prodromal cardiac sympathetic
involvement is suggested by work conducted in asymp-
tomatic brain donors who had incidental Lewy body dis-
ease (i.e., potentially a prodromal stage of PD) who show a
reduction of tyrosine hydroxylase-containing axons in the
myocardium of the heart (Iwanaga et al. 1999).
In addition to these sympathetic noradrenergic defi-
ciencies, recent in vivo imaging with 5-[11C]-methoxy-
donepezil has made it possible to measure peripheral
acetylcholinesterase density a marker of parasympathetic
function. Work in PD using this approach has shown sig-
nificantly decreased 11C-donepezil binding in the small
intestine and pancreas of PD stage patients (Fig. 3)
(Gjerløff et al. 2015). This data suggests that the patho-
physiology of PD also involves the parasympathetic
innervation (Fig. 4).
Adler et al. (2016) have shown that submandibular gland
needle biopsies were able to identify phosphorylated alpha-
synuclein staining in 74% of the early PD subjects (Fig. 5),
whilst other research teams have described phosphorylated
alpha-synuclein deposition across the myenteric plexus,
submucosal layer as well as the mucosal nerve fibers of the
intestine (Shannon et al. 2012). Involvement of skin with
accumulation of alpha-synuclein has also been described
(Gibbons et al. 2016).
The clinical translation: subtypes
The diagnostic concept of Parkinson’s disease is changing
and an ongoing revision of its diagnostic criteria by the
International Movement Disorders Society has included a
range of non-motor symptoms (NMS) as part of the core
parameters (Postuma et al. 2015). This would suggest that
there is a greater awareness of the clinical heterogeneity of
PD, which is no longer viewed as a disease with motor
features alone. The recognition mixed motor and non-
motor phenotypes have been well documented in the lit-
erature and many initial studies attempted to understand
these variances through a ‘‘matched groups’’ approach with
Fig. 2 Cardiac meta-(123)I-iodobenzylguanedine (MIBG) imaging.
a Shows a subject with normal visualisation of the heart (arrowed),
while b shows non-visualisation of the heart as in PD as evidence of
postganglionic peripheral sympathetic dysfunction Picture courtesy
nuclear imaging department, Kings College Hospital, London
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classifications based on predetermined patient attributes,
such as age of disease-onset, cognitive performance, motor
phenotype, and disease severity. However, all of these
approaches suffer from the limitations arising from the
prospective assumptions about the classification, namely
the arbitrary division of patients based on the criteria
adopted. To avoid this, more recent work has sought to
utilize data-driven methodologies, such as cluster analysis.
One recent systematic review of the cluster analyses
performed in PD has revealed that subgroups do appear to
exist and that there is a common division occurring
between a milder younger onset and a more aggressive
older onset phenotype (van Rooden et al. 2010). Results
obtained from individual studies have highlighted the
existence of four distinct PD subgroups, namely (1)
younger disease-onset, (2) tremor dominant, (3) non-tremor
dominant, and (4) rapid disease progression (Lewis et al.
2005; Reijnders et al. 2009; Selikhova et al. 2009). These
initial studies highlighted that whilst tremor dominant
patients have relative NMS sparing, the non-tremor dom-
inant subgroup is more associated with cognitive impair-
ment and mood disturbance. Indeed, more recent work has
identified a differential expression of mild cognitive
impairment across these subgroups, with the highest fre-
quency observed in the non-tremor dominant cluster, which
was also associated with a higher prevalence of freezing of
gait, hallucinations, daytime somnolence, and RBD com-
pared with other subgroups (Szeto et al. 2015).
To avoid the impact of dopaminergic therapy, some
authors have performed cluster analysis in untreated PD
patients, although there are still problems with this
Fig. 3 5-[11C]-methoxy-donepezil PET-imaging in normal subjects
(a) and Parkinson’s disease (b). b Showing reduced uptake of
pancreas and intestine Taken from Gjerløff et al. (2015)
Fig. 4 Peripheral sympathetic
and parasympathetic
dysfunction of the Parkinson’s




Fig. 5 Submandibular gland needle biopsy from a subject with PD
with immune-histochemical staining for phosphorylated alpha-synu-
clein showing positive inclusion. Arrow points to an immunoreactive
nerve fiber within a stromal nerve fascicle. Asterisks indicate
nonspecific immunoperoxidase staining of gland cell cytoplasm
Taken from Adler et al. (2016)
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approach. Using this strategy, motor and several non-motor
symptom dominant clusters have been identified in two
large studies (Erro et al. 2013; Pont-Sunyer et al. 2015),
whilst other observers have attempted to clinically define
the non-motor clusters to specific non-motor subtypes of
PD (Sauerbier et al. 2016; Marras and Chaudhuri 2016).
Heterogeneity is again evident in these analyses, and for
instance, Erro et al. (2015) reported that their non-motor
dominant cluster had urinary dysfunction, which predicted
a rapid progression rate of the motor syndrome of PD. In
the ONSET-PD study, specific non-motor PD clusters,
which ranged from cognitive and mood clusters to sensory,
RBD dominant, and autonomic dysfunction-related clusters
were reported which tallied well with the NMS dominant
subtypes described by Sauerbier et al. (2016). Indeed,
biomarker driven studies have now shown evidence that
these subtypes can be further defined by specific neuro-
chemical dysfunction, at least in part, suggesting that in
future, progression pattern of these specific NMS subtypes
could be examined.
It has been suggested that NMS subtypes may be more
stable over time compared to the motor subtypes PD as the
former is underpinned by specific patterns of neurotrans-
mitter pathway dysfunction (Marras and Chaudhuri 2016).
A proposed example is offered in Fig. 6.
Possible clinical consequences
Identification of specific NMS subtypes may, in future,
help fashion more personalized therapies and individual-
ized medicine (Schrag et al. 2015b). For example, some
might argue that a PD variant identified to have cognitive
dysfunction at onset is likely to have a more cholinergic
syndrome that would merit combined therapy with
dopaminergic and cholinesterase inhibitors. Moore and
Barker (2014) argue for robust multimodal biomarkers that
may predict the development of PD dementia and help
develop specific and individualized therapies. A stronger
clinical ‘‘sleep’’ phenotype (Sauerbier et al. 2016) would
possibly be underpinned by serotonergic raphe dysfunction
and may, therefore, have a narcoleptic phenotype (Pavese
et al. 2012; Ylikoski et al. 2015). In these patients, there
might even be an abnormal sensitivity to dopamine D3
Fig. 6 Proposed flowchart showing the various selective (does not
exclude overlap) neurotransmitter pathway dysfunction as delineated
by in vivo imaging or clinical tests and the resulting clinical
phenotype of NMS dominant subtypes. Dopamine deficiency
underpins the whole condition. The imaging correlates could emerge
as possible biomarkers in future MS motor syndrome. NMS non-
motor syndrome
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receptor agonists, which might, therefore, be preferably
avoided (Sauerbier et al. 2016).
Conclusion
It is crucial that the clinical heterogeneity of PD is better
recognized as it is likely that multimodal biomarker
methods will show specific patterns of underlying cerebral
and extra-cerebral neurotransmitter dysfunction. Such
findings would correlate well with specific clinical sub-
types of PD, particularly in the newly emerging concept of
non-motor subtypes. Clinically, the heterogeneity of PD is
also reflected by broad overlap of PD with parkinsonian
syndromes, such as dementia with Lewy bodies or
parkinsonian variants of multiple system atrophy, which is
reflected in the recent revision of the diagnostic criteria for
PD (POstuma et al. 2015). We acknowledge that, at this
time, there is no robust or convincing evidence base to
suggest that PD is definitively a multisystem disorder.
However, evidence provided in this review with conse-
quent abnormalities of functional networks within the brain
is likely to drive the heterogeneity of PD, with important
implications for clinical translational and prognostic
research for the future.
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